Go Pro
NASDAQ:MGX

Metagenomi Q2 2026 Earnings Report

Metagenomi logo
$1.34 +0.02 (+1.52%)
As of 09:55 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Metagenomi EPS Results

Actual EPS
N/A
Consensus EPS
-$0.57
Beat/Miss
N/A
One Year Ago EPS
N/A

Metagenomi Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.76 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Metagenomi Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Monday, August 10, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Metagenomi Earnings Headlines

The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.tc pixel
See More Metagenomi Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Metagenomi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metagenomi and other key companies, straight to your email.

About Metagenomi

Metagenomi (NASDAQ:MGX) (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors. The company works with manufacturers to enhance biofuel production, create greener chemical intermediates and develop more effective formulations for detergents, textiles and crop protection. In the biopharmaceutical realm, Metagenomi’s novel genome-editing components have the potential to drive next-generation gene therapies and precision medicine approaches by enabling targeted modifications in living cells.

Founded in 2019 and headquartered in South San Francisco, Metagenomi has rapidly expanded through strategic collaborations and research partnerships with industry leaders and academic institutions. The company’s management team combines deep expertise in genomics, computational biology and industrial biotechnology, positioning Metagenomi to serve global markets and address growing demand for sustainable, biologically derived solutions. As it advances its pipeline programs and broadens its partner network, Metagenomi continues to pursue breakthrough innovations that bridge metagenomics data with real-world manufacturing needs.

View Metagenomi Profile